Protalix BioTherapeutics Inc (AMEX:PLX) price on Wednesday, February 05, rose 5.95% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.67.
A look at the stock’s price movement, the close in the last trading session was $2.52, moving within a range at $2.55 and $2.7095. The beta value (5-Year monthly) was 0.672. Turning to its 52-week performance, $2.54 and $0.82 were the 52-week high and 52-week low respectively. Overall, PLX moved 25.94% over the past month.
Protalix BioTherapeutics Inc’s market cap currently stands at around $196.61 million, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 18.75M for the company’s revenue for the quarter, with a low and high estimate of 18.21M and 19.29M respectively. The average forecast suggests up to a 78.77% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 53.93M, representing a -17.66% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that PLX is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
PLX’s current price about 14.25% and 33.43% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 74.26, while 7-day volatility ratio is 5.66% and 5.87% in the 30-day chart. Further, Protalix BioTherapeutics Inc (PLX) has a beta value of 0.72, and an average true range (ATR) of 0.13.
If we refocus on Protalix BioTherapeutics Inc (AMEX:PLX), historical trading data shows that trading volumes averaged 0.68 over the past 10 days and 532.15K over the past 3 months. The company’s latest data on shares outstanding shows there are 73.63 million shares.
The 7.56% of Protalix BioTherapeutics Inc’s shares are in the hands of company insiders while institutional holders own 5.54% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 3.1 million on 2024-10-31, giving us a short ratio of 22.71. The data shows that as of 2024-10-31 short interest in Protalix BioTherapeutics Inc (PLX) stood at 440.99998000000005 of shares outstanding, with shares short falling to 3.13 million registered in 2024-09-30. Current price change has pushed the stock 42.02% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PLX stock continues to rise going into the next quarter.
